Skip to main content
. Author manuscript; available in PMC: 2020 Jan 28.
Published in final edited form as: J Invest Dermatol. 2018 Dec 10;139(6):1339–1348. doi: 10.1016/j.jid.2018.11.028

Figure 4. TA99-mTNF is able to boost the therapeutic effect of IgG2a(TA99) on B16F10 tumors.

Figure 4

A, Therapy in B16F10 melanoma bearing C57/BL6 mice with IgG2a(TA99) as single agent. Mice were injected three times intravenously every 48 hours with 300 μg IgG2a(TA99) or saline (arrows). Therapy started at day 3 (red arrows) or at day 6 (black arrows) after tumor implantation. Data represent mean tumor volume ± SEM, n = 5 mice per group.

B, Example of coat depigmentation in C57/BL6 mouse treated with IgG2a(TA99). Mice were shaved on day -1 over the right flank and on the back. C, Left: Therapy in B16F10 melanoma bearing C57/BL6 mice with IgG2a(TA99), TA99-mTNF as single agents or in combination. Mice were injected three times intravenously every 72 hours with 300 μg IgG2a(TA99), 7 μg TA99-mTNF or saline (red arrows). Data represent mean tumor volume ± SEM. Right: Toxicity monitoring by alterations in body weight change during therapy represented as mean % weight change ± SEM, n = 5 mice per group for IgG2a(TA99) + TA99-mTNF combination and TA99-mTNF monotherapy, n = 4 mice per group for Saline, IgG2a(TA99) monotherapy and TA99-mTNF monotherapy after day 13 (*). D, Left: Therapy in B16F10 melanoma bearing C57/BL6 mice with IgG2a(TA99), TA99-mTNF as single agents or in combination. Mice were injected three times intravenously every 48 hours with 300 μg IgG2a(TA99), 5.5 μg TA99-mTNF or saline (red arrows). For the combination treatment TA99-mTNF was injected either 24 hours before or immediately after IgG2a(TA99) administration. Data represent mean tumor volume ± SEM. Right: Toxicity monitoring by alterations in body weight change during therapy represented as mean % weight change ± SEM, n = 5 mice per group, n = 4 mice per group for Saline, TA99-mTNF monotherapy after day 16 and day 13 respectively (*).